Last reviewed · How we verify
Dexamethasone, Ondansetron, Aprepitant
This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different mechanisms: glucocorticoid, 5-HT3 antagonist, and NK1 antagonist pathways.
This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different mechanisms: glucocorticoid, 5-HT3 antagonist, and NK1 antagonist pathways. Used for Prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy, Prevention of acute and delayed CINV.
At a glance
| Generic name | Dexamethasone, Ondansetron, Aprepitant |
|---|---|
| Also known as | Decadron, Zofran, Emend |
| Sponsor | Ottawa Hospital Research Institute |
| Drug class | Antiemetic combination (corticosteroid + 5-HT3 antagonist + NK1 antagonist) |
| Target | Glucocorticoid receptor, 5-HT3 receptor, NK1 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology / Supportive Care |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone is a corticosteroid that reduces inflammation and modulates emetic pathways. Ondansetron blocks 5-HT3 serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract. Aprepitant antagonizes neurokinin-1 (NK1) receptors in the central nervous system. Together, these agents target multiple pathways involved in nausea and vomiting, providing superior antiemetic coverage compared to monotherapy.
Approved indications
- Prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy
- Prevention of acute and delayed CINV
Common side effects
- Headache
- Fatigue
- Constipation
- Diarrhea
- Dizziness
Key clinical trials
- Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile (PHASE2)
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients (PHASE3)
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (PHASE3)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery. (PHASE4)
- Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: